六氟化硫与全氟丁烷超声造影诊断高危人群肝细胞癌的比较
前瞻性研究纳入59例高危受试者,同日行全氟丁烷与六氟化硫超声造影,按CEUS LI-RADS v2017分类。全氟丁烷超声造影诊断肝细胞癌的敏感度79%高于六氟化硫的54%,两者特异度均为100%,全氟丁烷的廓清时间更晚。
要点
- 全氟丁烷超声造影诊断肝细胞癌敏感度79%,高于六氟化硫的54%,特异度均为100%。
- 肝细胞癌在全氟丁烷超声造影中廓清更晚,中位时间101秒,晚于六氟化硫的84秒。
- Kupffer期低增强在恶性病变中占92%,在良性病变中占33%(操作者判读)。
关键影像表现/征象
- 非环状动脉期高增强在两种造影剂中检出率相同:操作者判读为95%(41/43),复核者判读为88%(38/43)。
- 肝细胞癌中,全氟丁烷超声造影出现晚期(≥60秒)轻度廓清者(操作者34例、复核者33例)多于六氟化硫超声造影(操作者24例、复核者26例)(P=0.04或P=0.12)。
- 肝细胞癌廓清时间全氟丁烷超声造影中位101秒±11,晚于六氟化硫超声造影中位84秒±5(P=0.04)。
- Kupffer期低增强在恶性病变中占92%(49/53,操作者与复核者相同),在良性病变中操作者判读占33%(2/6)、复核者判读占16%(1/6)。
诊断标准与关键数值
- 全氟丁烷超声造影诊断肝细胞癌敏感度79%(34/43;95%CI:64%,90%),高于六氟化硫超声造影54%(23/43;95%CI:38%,67%;P=0.01)。
- 两种造影剂诊断肝细胞癌特异度均为100%(95%CI:79%,100%)。
临床应用与阅片要点
- 按CEUS LI-RADS 2017算法,全氟丁烷超声造影对高危人群肝细胞癌的无创诊断效能高于六氟化硫超声造影,且特异度未降低。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
Background Perfluorobutane (PFB) and sulfur hexafluoride (SHF) have different physiologic characteristics, but it is unclear whether hepatocellular carcinomas (HCCs) show similar wash-in and washout patterns to both contrast agents at US. Purpose To investigate Contrast-Enhanced US Liver Imaging Reporting and Data System (LI-RADS) version 2017 HCC categorization by comparing PFB-enhanced US and SHF-enhanced US in participants at high risk for HCC. Materials and Methods In this prospective study conducted from February to August 2019, participants at high risk for HCC with treatment-naive hepatic observations (≥1 cm) categorized as LR-3, LR-4, LR-5, or LR-M (intermediate probability of HCC, probable HCC, definitely HCC, and probably malignant but not HCC specific, respectively) on cross-sectional images were screened. They underwent same-day PFB-enhanced US and SHF-enhanced US. Arterial phase hyperenhancement (APHE), washout time and degree, and echogenicity in the Kupffer phase (PFB-enhanced US) were evaluated and categorized by the operator using CEUS LI-RADS, who referred to the radiologist who performed the contrast-enhanced US, and by a reviewer. Diagnostic performance was analyzed using the McNemar test. Results Fifty-nine participants were evaluated (43 with HCC, 10 with non-HCC malignancies, six with benign findings). Nonrim APHE was identically observed in 95% (41 of 43, operator) or 88% (38 of 43, reviewer) of HCCs with both contrast agents. Among 43 HCCs, late (≥60 seconds) and mild washout were more frequent with PFB-enhanced US (34 with operator, 33 with reviewer) than with SHF-enhanced US (24 with operator, 26 with reviewer) (P = .04 or P = .12). The washout time for HCCs was later at PFB-enhanced US (median, 101 seconds ± 11) than at SHF-enhanced US (median, 84 seconds ± 5; P = .04). Sensitivity (34 of 43; 79%; 95% confidence interval [CI]: 64%, 90%) was higher with PFB-enhanced US than with SHF-enhanced US (23 of 43; 54%; 95% CI: 38%, 67%; P = .01). Specificity was 100% (95% CI: 79%, 100%) with both. Hypoenhancement in the Kupffer phase was more common in malignant (49 of 53 [92%] for both operator and reviewer) than in benign (two of six [33%] for operator, one of six [16%] for reviewer) lesions. Conclusion On the basis of the Contrast-Enhanced US Liver Imaging Reporting and Data System version 2017 algorithm, noninvasive US diagnosis of hepatocellular carcinoma by using perfluorobutane-enhanced US had higher diagnostic performance than sulfur hexafluoride-enhanced US, without loss of specificity. © RSNA, 2020 Online supplemental material is available for this article. See also the editorial by Kim and Jang in this issue.
引用
- Kang HJ, Lee JM, Yoon JH, et al. Contrast-enhanced US with Sulfur Hexafluoride and Perfluorobutane for the Diagnosis of Hepatocellular Carcinoma in Individuals with High Risk. Radiology. 2020. PMID: 32749211. doi:10.1148/radiol.2020200115
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。